Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

This study tests a combination of drugs — venetoclax, cladribine, cytarabine, and azacitidine — for patients with newly diagnosed acute myeloid leukemia (AML) who are not suitable for or do not want intensive chemotherapy. It focuses on certain subtypes including monocytic AML and AML with specific genetic mutations. **You may be eligible if...** - You have newly diagnosed AML with monocytic features or specific signaling mutations (such as KRAS, NRAS, FLT3, NF1) - You are not a candidate for intensive chemotherapy (e.g., due to age 75+, heart problems, poor performance status, or liver/kidney issues) - You are 18 or older - Your organ function meets study requirements **You may NOT be eligible if...** - You are suitable for and willing to undergo standard intensive chemotherapy - You have active, uncontrolled infections or other serious medical conditions - You are pregnant or breastfeeding - You have previously received treatment for AML Talk to your doctor to see if this trial is right for you.